Comparison
Brand-Name vs Compounded GLP-1
Same fields, same evidence rules, both sides. No preselected winner.
This comparison sets out where the two options genuinely differ — mechanism, regulatory status, evidence base, cost path and practical trade-offs — and where the difference is smaller than it is usually presented. It does not recommend one for you.
| Attribute | FDA-approved tirzepatide (Zepbound, Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | Approved finished drug product | Not an FDA-approved product |
| Generic equivalent | No generic tirzepatide exists | Not a generic and not therapeutically equivalent |
| Manufacturing standard | Manufactured under CGMP | Depends on the compounder's registration class |
| Clinical trial evidence | Studied in the registration trials | Trials studied the approved product, not this preparation |
| Labelling | FDA-approved labelling | Supplied by the compounder |
| Presentation | Manufacturer's pens or vials | Varies; multi-dose vials add a measuring step |
| Price read on the seller’s own page | — | — |
A dash means no figure held. How we grade evidence.
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
- FDA registered outsourcing facilitiesConfirms a facility is currently registered under 503B, and links the searchable product report database. Registration is not FDA approval and is not evidence of CGMP compliance.
- FDA outsourcing facility registration Q&AThe agency's own explanation of exactly what registration does and does not mean. Worth reading before accepting any provider's characterisation of its pharmacy.
- NABP directory of state boards of pharmacyRoutes you to the board that licenses a pharmacy, and to its licensee and nonresident registers. Check the licence is current, not merely present.
- FSMB directory of state medical boardsRoutes you to the board that licenses a prescriber, and to its public licence lookup. An NPI number is identity in a national registry, not a licence.
Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Show this figure as a table
| Item | Option A | Option B |
|---|---|---|
| Medication | not captured | not captured |
| Required fees | not captured | not captured |
| Twelve-month total | not captured | not captured |
The short version
Brand-name GLP-1 medicines are FDA-approved finished products. They include Wegovy and Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide) and Lilly's daily pill Foundayo. Compounded semaglutide and compounded tirzepatide are pharmacy preparations made with the drugs in those products. They are not FDA-approved, they are not generics, and they are not the same products. There is no compounded version of Foundayo.
The brand route makes sense when coverage or a program cuts the price. The clearest case is the Medicare GLP-1 Bridge: a $50 copay for Foundayo, Wegovy or the Zepbound KwikPen from July 1, 2026 to December 31, 2027, for eligible enrollees. It also makes sense if you want the product the trials studied. The compounded route is mainly a cash-price decision. It brings less assurance about how the product was made, and the FDA has not finished deciding the regulatory position for either drug.
Where they actually differ
- Approval and labelled uses. Each brand product has its own approved uses. Compounded semaglutide and tirzepatide have none.
- Medicare coverage. The GLP-1 Bridge covers three brand products and no compounded ones. Even Zepbound is covered only as the KwikPen, not as vials.
- The ingredient. FDA has warned that some compounded semaglutide is made from salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in approved products. See FDA's page on compounded GLP-1s.
- Pills and drops. Foundayo is an approved oral GLP-1. Compounded "oral", sublingual and dissolving-tablet versions of semaglutide or tirzepatide have no trial evidence that they are absorbed. See GLP-1s without needles.
- The shortage route. FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage in February 2025. That closed the wider compounding route for both. In April 2026 FDA also proposed not to place semaglutide, tirzepatide or liraglutide on the 503B bulks list.
Where they are more similar than claimed
- The drug comparison is separate from the brand comparison. In SURMOUNT-5, tirzepatide produced a larger average weight loss than semaglutide (−20.2% vs −13.7% at 72 weeks). That is a difference between two drugs, both tested as manufacturers' products. It says nothing about compounded tirzepatide against brand semaglutide, which no trial has tested.
- Injections work the same way. Brand and compounded injectables are both given once a week under the skin. The vial-and-syringe step is the practical difference.
- The same oversight is needed. Both routes need a prescription, a dose plan and follow-up from a licensed clinician.
- A brand name is not proof. FDA has warned that counterfeit Ozempic has been marketed in the US. A brand pen from an unlicensed seller is not safer than a properly sourced prescription. See counterfeit GLP-1s.
- Side effects. Stomach and bowel effects dominate across this class.
Cost, all-in
Brand prices depend on the drug and your coverage. Compounded prices depend on the drug and the program.
| Route | What you pay | Read |
|---|---|---|
| Medicare GLP-1 Bridge: Foundayo, Wegovy or Zepbound KwikPen | $50 copay, eligible enrollees | July 1, 2026 to Dec 31, 2027 |
| Zepbound KwikPen, Lilly self-pay | $299 to $449 a fill, with conditions | Oct 15, 2026 |
| Compounded tirzepatide, 33 programs | $69 to $299 a month all-in; median $149 | Oct 15, 2026 |
Our price index covers tirzepatide. We do not quote Wegovy, Ozempic or compounded semaglutide prices here, because we have not read them under the same method. Lilly's self-pay savings end on December 31, 2026, and the $449 tier needs each refill within 45 days.
The current tirzepatide figures are in the price index. For coverage, see insurance and GLP-1s.
Who each option suits
These are situations, not recommendations. Which drug suits you is a decision for you and your clinician. Brand versus compounded comes after that.
- You are on Medicare and have obesity without type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. The Bridge may give you Foundayo, Wegovy or the Zepbound KwikPen for $50. Check eligibility with CMS.
- You are on Medicare and have one of those three conditions. You are not eligible for the Bridge, but your Part D plan might cover a GLP-1.
- You want to avoid injections. Foundayo is the approved oral option in this list. Compounded oral GLP-1 products have no trial evidence behind them.
- Your commercial plan covers a GLP-1. Check which one is on its formulary before you compare cash prices.
- You pay cash. Compounded programs are usually cheaper. Check the pharmacy, the ingredient and the price at your maintenance dose.
What the evidence does not settle
- Brand versus compounded results. No randomised trial has compared compounded semaglutide or compounded tirzepatide with the approved products.
- Non-injected compounded forms. Whether compounded oral, sublingual or dissolving-tablet GLP-1s reach the bloodstream in useful amounts has not been shown.
- Switching mid-course. Moving between brand and compounded, or between compounded products at different concentrations, has not been studied. The conversion depends on reading the concentration correctly.
- Added ingredients. Benefits claimed for vitamins or amino acids added to compounded GLP-1s are untested.
- The regulatory outcome. FDA's April 2026 proposal covers semaglutide, tirzepatide and liraglutide. Comments closed on July 30, 2026, and a Federal Register search on November 9, 2026 found no final decision.
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Questions readers actually ask
Which one is better?
Neither, in the abstract. The comparison table shows where each is stronger on a defined field; the right answer depends on your dose, your billing term and what your clinician advises.
Is one of these sponsoring this page?
No. No provider can buy a score, a placement or a review on this site.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Zepbound vs Compounded TirzepatideComparisons
- Zepbound vs Compounded TirzepatidePillar / Money
- Ro Body vs Mochi HealthComparisons
Related coverage
Tirzepatide Ranked. “Brand-Name vs Compounded GLP-1.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compare/brand-vs-compounded-glp1/
Quote the capture date beside a figure, not the date you read this page. Why.